doi: 10.1093/infdis/136.supplement_3.s731.
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity
- PMID: 606798
- DOI: 10.1093/infdis/136.supplement_3.s731
Item in Clipboard
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity
J Infect Dis.
1977 Dec.
Abstract
The total multicenter data from trials with inactivated monovalent influenza A/New Jersey/76 virus vaccine in 2,326 normal children were collected and summarized at Vanderbilt University (Nashville, Tenn.). These combined data provided the best measure of the relative antigenicity and reactogenicity of each manufacturer's vaccine. Children younger than 10 years of age were shown to have vaccine-associated reactions to doses of whole-virus vaccine containing as little as 50 chick cell-agglutinating units. Split-virus vaccines were well tolerated in doses eight times as high. No vaccine was satisfactorily antigenic in a single dose. A two-dose regimen of split-virus vaccine was antigenic, and this regimen was not associated with acute reactions.
Similar articles
-
Clinical trials with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza vaccines in Los Angeles children.J Infect Dis. 1977 Dec;136 Suppl:S661-4. doi: 10.1093/infdis/136.supplement_3.s661. J Infect Dis. 1977. PMID: 342631 Clinical Trial.
-
IgM and IgG antibody responses after immunization of children with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza virus vaccines.J Infect Dis. 1977 Dec;136 Suppl:S665-71. doi: 10.1093/infdis/136.supplement_3.s665. J Infect Dis. 1977. PMID: 342632 Clinical Trial.
-
Reactivity and immunogenicity of monovalent A/New Jersey/76 influenza virus vaccines in children.J Infect Dis. 1977 Dec;136 Suppl:S563-70. doi: 10.1093/infdis/136.supplement_3.s563. J Infect Dis. 1977. PMID: 342628 Clinical Trial.
-
Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety.Rev Infect Dis. 1983 Jul-Aug;5(4):758-64. doi: 10.1093/clinids/5.4.758. Rev Infect Dis. 1983. PMID: 6353530 Clinical Trial.
-
Serologic responses to split and whole swine influenza virus vaccines in light of the next influenza pandemic.J Infect Dis. 1977 Dec;136 Suppl:S683-5. doi: 10.1093/infdis/136.supplement_3.s683. J Infect Dis. 1977. PMID: 342633 Review. No abstract available.
Cited by
-
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.Vaccine. 2009 Nov 5;27(47):6642-8. doi: 10.1016/j.vaccine.2009.03.015. Epub 2009 Mar 25. Vaccine. 2009. PMID: 19773098 Free PMC article. Clinical Trial.
-
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.PLoS Pathog. 2008 Aug 29;4(8):e1000138. doi: 10.1371/journal.ppat.1000138. PLoS Pathog. 2008. PMID: 18769719 Free PMC article.
-
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.PLoS One. 2009 Jun 19;4(6):e5984. doi: 10.1371/journal.pone.0005984. PLoS One. 2009. PMID: 19543385 Free PMC article.
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.MMWR Recomm Rep. 2017 Aug 25;66(2):1-20. doi: 10.15585/mmwr.rr6602a1. MMWR Recomm Rep. 2017. PMID: 28841201 Free PMC article.
-
Vaccination against virus diseases.Soz Praventivmed. 1979 Oct;24(5):335-45. doi: 10.1007/BF02083602. Soz Praventivmed. 1979. PMID: 394510 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
